FOR IMMEDIATE RELEASE

MEDIA CONTACT:
Kathy Markham
Marketing Manager
Phone: 253.274.7165
Email: KMarkham@Unigen.net

Unigen’s UP1307 Skin Cream Excels in Clinical Trial;
Results Published in August 2018 Journal of Clinical and Aesthetic Dermatology

Significant clinical results indicate Unigen’s newest skin care ingredient, UP1307, is effective in promoting skin hydration, firmness, and elasticity, with associated improvement in cellulite appearance. In the recently concluded clinical trial, UP1307 resulted in visibly superior results compared to similar cellulite products on the market, according to Dr. Qi Jia, Unigen’s Chief Scientific Officer.

Dr. Jia stated that the skin is where initial visual signs of aging manifest, including increased skin dryness and decreased firmness and elasticity. Cellulite is another characteristic of skin aging and presents as a skin condition characterized by changes in the skin morphology due to excessive lipid deposition in subcutaneous adipose tissue.

“We sought to assess the effectiveness of our UP1307 topical botanical composition on cellulite, skin hydration, firmness, and elasticity after two, four, and eight weeks of use compared to a commercial cellulite cosmetic product,” explained Dr. Jia. “At Week 8, 44.4- and 42.7-percent improvement in appearance of cellulite was observed for the UP1307 cream and the active comparator group, respectively.”

The study was a single-blind, randomized, controlled study conducted on subjects with mild-to-severe cellulite in a pre-targeted area of the body. Subjects were treated for eight weeks with a topical botanical cream formulated with UP1307 composition and a commercial cellulite cosmetic product. A total of 44 women 18 to 59 years of age were enrolled in the study. Test products were applied twice per day to the targeted cellulite area, as identified by dermatologists. Measurements using Corneometer® (for skin hydration) and Cutometer® (for skin elasticity and firmness) were carried out at each visit, in addition to expert clinical grader evaluations for cutaneous changes and cellulite. Outcomes were also assessed by study subjects using subject questionnaires. Study subjects reported significant improvement in skin hydration, firmness, and elasticity over time. Findings were corroborated with objective instrumental measurements.

Complete results from the UP1307 clinical trial are published in the August 2018 edition of Journal of Clinical and Aesthetic Dermatology 2018:11(8); 51-57. To obtain an e-print, please send your request to Contact@unigen.net.

NOTE: Visit Unigen (Booth 2951) at SupplySide West 2018 (November 8-9, Mandalay Bay Convention Center, Las Vegas, NV).
### About Unigen
Unigen discovers, develops and manufactures proprietary natural-product active ingredients for dietary supplements, cosmetic and personal care products, prescription medical food and botanical drug products. The Company discovers its ingredients through our high throughput screening PhytoLogix™ approach applied to a proprietary well-annotated collection of botanicals and a legacy mining approach applied to botanicals having known medicinal benefits. Mechanism of action, safety and efficacy are documented with extensive preclinical in vitro and in vivo testing and by human clinical studies. Unigen protects its discoveries with issued patents and patent filings in all major territories, and manufactures its products to GMP standards. Unigen commercializes its proprietary ingredients through licensing and ingredient supply alliances with commercial partners engaged in the manufacture, distribution and marketing of end-products in each of Unigen’s target markets. [www.Unigen.net](http://www.Unigen.net)